Browsing by Author "Ríos Raggio, Mariana"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Concanavalin-A Induces Granulosa Cell Death and Inhibits FSH-Mediated Follicular Growth and Ovarian Maturation in Female Rats
    (2013) Velásquez Opazo, Ethel Virginia; Ríos Raggio, Mariana; Ortíz Scarlazetta, María Elena; Lizama, Carlos; Orge, Felipe; Oliva, Barbara; Orellana Walden, Renán Felipe; Villalón, Manuel J.; Moreno Mauro, Ricardo D.; Owen, Gareth Ivor; Núñez, Elizabeth; Abramovich, Dalhia; Tesone, Marta, Rokka, Anne; Corthals, Garry; Croxatto A., Horacio; Parborell, Fernanda
  • Thumbnail Image
    Item
    Epithelial Cell Culture from Human Adenoids : A Functional Study Model for Ciliated and Secretory Cells
    (2013) González, Claudia; Espinosa de la Fuente, Marisol; Sánchez Dueñas, María Trinidad; Droguett, Karla; Ríos Raggio, Mariana; Fonseca Arrieta, María Ximena; Villalón, Manuel J.
  • No Thumbnail Available
    Item
    Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
    (2021) Bueno Ramírez, Susan; Abarca Villaseca, Katia; González Adonis, Pablo Andrés; Gálvez Arriagada, Nicolás Marcelo Salvador; Soto Ramírez, Jorge Andrés; Duarte Peñaloza, Luisa Fernanda; Schultz Lombardic, Bárbara M.; Pacheco, Gaspar A.; González Carreño, Liliana Andrea; Vázquez, Yaneisi; Ríos Raggio, Mariana; Melo González, Felipe; Rivera Pérez, Daniela; Iturriaga, Carolina; Urzúa Acevedo, Marcela del Pilar; Domínguez De Landa, María Angélica; Andrade Parra, Catalina Andrea; Berríos Rojas, Roslye; Canedo Marroquín, Giselda; Covián, Camila
    The ongoing COVID-19 pandemic has had a significant impact worldwide, with an incommensurable social and economic burden. The rapid development of safe and protective vaccines against this disease is a global priority. CoronaVac is a vaccine prototype based on inactivated SARS-CoV-2, which has shown promising safety and immunogenicity profiles in pre-clinical studies and phase 1/2 trials in China. To this day, four phase 3 clinical trials are ongoing with CoronaVac in Brazil, Indonesia, Turkey, and Chile. This article reports the safety and immunogenicity results obtained in a subgroup of participants aged 18 years and older enrolled in the phase 3 Clinical Trial held in Chile.